Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants

Brain Research

Volumn 682, Issue 1-2, 1995, Pages 133-143

  Pardo, B ^a   Mena, M A ^a   Casarejos, M J ^a   Paino C L ^a   De Yebenes J G ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Grupo de Trabajo Ecografía SoMaMFyC   (Spain)

Author keywords

Ascorbic acid; Dopamine neuron; L DOPA; Neurotoxicity; Parkinson's disease; Rat mesencephalic cell culture

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; LEVODOPA; MAZINDOL; SODIUM METABISULFITE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; EMBRYO; MESENCEPHALON; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMAL; ANTIOXIDANTS; CELLS, CULTURED; DOPAMINE AGENTS; DOPAMINE UPTAKE INHIBITORS; DYES; IMMUNOHISTOCHEMISTRY; LEVODOPA; MAZINDOL; MESENCEPHALON; NERVE TISSUE PROTEINS; NEURONS; NEUROTRANSMITTERS; QUINONES; RATS; RATS, SPRAGUE-DAWLEY; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TRYPAN BLUE;

EID: 0029053242     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(95)00341-M     Document Type: Article

References (58)

1. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do non-dopaminergic lesions play a role?
2. Does levodopa aggravate Parkinson's disease?
3. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine
4. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye-binding
5. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine: evidence for selective degeneration of catecholamine neurons
6. MAP2 is localized to the dendrites of hippocampal neurons which develop in culture
7. Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures
8. Superoxide dismutase and Parkinson's disease
9. Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesia or dementia in Parkinson's disease
10. Glutathione peroxidase, glial cells and Parkinson's disease
11. Preferential localization of copper zinc superoxide dismutase in the vulnerable cortical neurons in Alzheimer's disease
12. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
13. Staging and dissection of rat embryos
14. Should levodopa therapy for parkinsonism be started early or else? Evidence against early treatment
15. Pre- and postsynaptic neurotoxic effects of dopamine by intrastriatal injection
16. Autoxidation versus covalent binding of quinone as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds towards C1300 neuroblastoma cells in vitro
17. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
18. Oxidants and the central nervous system some fundamental questions Is oxidant damage relevant to Parkinson's disease Alzheimer's disease traumatic injury or stroke?
19. Long-term administration of levodopa does not damage dopaminergic neurons in the mouse
20. 6-Hydroxydopamine: evidence for superoxide radical as an oxidative intermediate
21. Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis
22. Parkinsonism treated with levodopa, progression and mortality
23. Biochemical pathophysiology of Parkinson's disease
24. A simple method of reducing the fading of immunofluorescence during microscopy
25. Semiquinone anion radicals from addition of amino acids, peptides and proteins to quinones derived from oxidation of catechols and catecholamines
26. Ascorbic acid in mesencephalic cultures: effects on dopaminergic neurons development
27. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy
28. A striatal-derived neurotrophic factor: relationship to Parkinson's disease
29. Vitamin E, ascorbate, glutathione, glutathione disulfide and enzimes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain
30. Long-term follow up of early dopa treatment in Parkinson's disease
31. Microtubule-associated protein 2 and tubulin are differentially distributed in the dendrites of developing neurons
32. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease
33. Neurotoxicity of levodopa on catecholamine-rich neurons
34. Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid
35. Toxic effects of environmental neurotoxins related to 1-methyl-4-phenylpiridinium on cultured rat dopaminergic neurons
36. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture
37. Toxic effects of iron for cultured mesencephalic dopaminergic neurons derived from rat embryonic brains
38. 6-hydroxydopamine toxicity to dopamine neurons in culture: potentiation by the addition of superoxide dismutase andN-acetylcysteine
39. Toxic and protective effects of L-DOPA on mesencephalic cell cultures
40. Local support cells promote survival of substantia nigra dopaminergic neurons in culture
41. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line
42. Parkinson's disease: a disorder due to nigral glutathione deficiency?
43. Nigrostriatal dopamine neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically
44. Specific stimulation of in vitro maturation of mesencephalic dopaminergic neurons
45. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 Kg) plus decarboxylase inhibitor over a four-year period
46. Cell-type-specific markers for distinguishing and studying neurons and the major classes of glial cells in culture
47. A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission
48. Catecholamine toxicity in cerebral cortex in dissociated cell culture
49. Maintenance of neuronal glutathione by glial cells
50. Micronutrient homeostatis in mammalian brain and cerebrospinal fluid
51. Chronic levodopa impairs morphological development of embryonic dopamine neurons
52. Iron-dependent cytotoxic effects of DOPA on cultured neurons of the dorsal root ganglia
53. Dopa and dopamine cause cultured neuronal death in the presence of iron
54. Use of intracerebral injection of 6-hydroxydopamine as a tool for morphological and functional studies on central catecholamine neurons
55. Effects of 6-hydroxydopamine on catecholamine neurons in the rat brain
56. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project
57. The possible role of iron in the etiopathology of Parkinson's disease
58. Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting